Maria P. Meivita
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Maria P. Meivita has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Desmond. K. Loke
Department of Science, Mathematics and Technology, Singapore University of Technology and Design, Singapore 487372, Singapore
1 shared publication - Fitya Syarifa Mozar
Bioinformatics and Data Science Research Center, Bina Nusantara University, Jakarta 11480, Indonesia
1 shared publication - Lunna Li
Thomas Young Centre and Department of Chemical Engineering, University College London, London WC1E 7JE, UK
1 shared publication - Natasa Bajalovic
Department of Science, Mathematics and Technology, Singapore University of Technology and Design, Singapore 487372, Singapore
1 shared publication - Shao-Xiang Go
Department of Science, Mathematics and Technology, Singapore University of Technology and Design, Singapore 487372, Singapore
1 shared publication
Latest Publications
- Open Access
Energy-Efficient and Effective MCF-7 Cell Ablation and Electrothermal Therapy Enabled by M13–WS2–PEG Nanostructures
Thermal agents (TAs) have exhibited promise in clinical tests when utilized in cancer thermal therapy (TT). While rapid degradation of TAs may address safety concerns, it limits the thermal stability required for effective treatment. TAs, which possess exceptional thermal stability, experience gradual deterioration. There are few approaches that effectively address the trade-off between improving thermal stability and simultaneously boosting material deterioration. Here, we control the thermal character of tungsten disulfide (WS2)-based 2D materials by utilizing an M13 phage through Joule heating (the M13–WS2–PEG nanostructures were generated and termed a tripartite (T) nanostructure), and developed a T nanostructure-driven TT platform (we called it T-TT) for efficient thermal ablation of clinically relevant MCF-7 cells. A relative cell viability of ~59% was achieved, as well as onset time of degradation of ~0.5 week. The T-TT platform also discloses an energy density of 5.9 J/mL. Furthermore, the phage-conjugated WS2 can be utilized to achieve ultrasound imaging for disease monitoring. Therefore, this research not only presents a thermal agent that overcomes TA limitations, but also demonstrates a practical application of WS2-type material system in ultra-energy efficient and effective cancer therapy.
Open AccessEnergy-Efficient and Effective MCF-7 Cell Ablation and Electrothermal Therapy Enabled by M13–WS2–PEG Nanostructures
Thermal agents (TAs) have exhibited promise in clinical tests when utilized in cancer thermal therapy (TT). While rapid degradation of TAs may address safety concerns, it limits the thermal stability required for effective treatment. TAs, which possess exceptional thermal stability, experience gradual deterioration. There are few approaches that effectively address the trade-off between improving thermal stability and simultaneously boosting material deterioration. Here, we control the thermal character of tungsten disulfide (WS2)-based 2D materials by utilizing an M13 phage through Joule heating (the M13–WS2–PEG nanostructures were generated and termed a tripartite (T) nanostructure), and developed a T nanostructure-driven TT platform (we called it T-TT) for efficient thermal ablation of clinically relevant MCF-7 cells. A relative cell viability of ~59% was achieved, as well as onset time of degradation of ~0.5 week. The T-TT platform also discloses an energy density of 5.9 J/mL. Furthermore, the phage-conjugated WS2 can be utilized to achieve ultrasound imaging for disease monitoring. Therefore, this research not only presents a thermal agent that overcomes TA limitations, but also demonstrates a practical application of WS2-type material system in ultra-energy efficient and effective cancer therapy.